1045 related articles for article (PubMed ID: 15828898)
21. Vitamin D treatment in chronic kidney disease.
Andress DL
Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ogata H; Koiwa F; Ito H; Kinugasa E
Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
[TBL] [Abstract][Full Text] [Related]
23. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
24. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
Yaginuma T; Yamamoto H
Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
[TBL] [Abstract][Full Text] [Related]
25. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
Cunningham J; Locatelli F; Rodriguez M
Clin J Am Soc Nephrol; 2011 Apr; 6(4):913-21. PubMed ID: 21454719
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
Górriz JL; Molina P; Bover J; Barril G; Martín-de Francisco AL; Caravaca F; Hervás J; Piñera C; Escudero V; Molinero LM;
Nefrologia; 2013 Jan; 33(1):46-60. PubMed ID: 23364626
[TBL] [Abstract][Full Text] [Related]
27. Prevention of secondary hyperparathyroidism in hemodialysis patients: the key role of native vitamin D supplementation.
Jean G; Vanel T; Terrat JC; Chazot C
Hemodial Int; 2010 Oct; 14(4):486-91. PubMed ID: 20955282
[TBL] [Abstract][Full Text] [Related]
28. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.
Wolf M; Thadhani R
Semin Dial; 2005; 18(4):302-6. PubMed ID: 16076353
[TBL] [Abstract][Full Text] [Related]
29. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
[TBL] [Abstract][Full Text] [Related]
30. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
Shastri J; Tran A; Covit A; Pepe J; Sherman RA
J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302
[TBL] [Abstract][Full Text] [Related]
31. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
Mehrotra R
J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
[TBL] [Abstract][Full Text] [Related]
32. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
[TBL] [Abstract][Full Text] [Related]
33. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
34. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
Fukagawa M; Komaba H; Kakuta T
Expert Opin Pharmacother; 2013 May; 14(7):863-71. PubMed ID: 23521343
[TBL] [Abstract][Full Text] [Related]
35. New approaches to treatment of secondary hyperparathyroidism.
Locatelli F; Limardo M; Pontoriero G
Curr Opin Investig Drugs; 2008 Apr; 9(4):363-70. PubMed ID: 18393103
[TBL] [Abstract][Full Text] [Related]
36. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
37. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
[TBL] [Abstract][Full Text] [Related]
38. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
39. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
Drüeke TB; Ritz E
Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
[TBL] [Abstract][Full Text] [Related]
40. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
Okada N; Tsubakihara Y
Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]